NURC
NOTICE OF UPDATED REGISTRATION CONFIRMATION EMAILED
04/21/2026
Back to search
Official data from USPTO
N NS PHARMA
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: US
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
25
Latest update
04/21/2026
Classification
Registered
Trademark type
Combined
Nice classes
5
Filing date
01/15/2025
Registration date
12/02/2025
Expiration date
-
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Complete case details
Structured fields from the responsible authority and the official record.
Status date
12/02/2025
Last transaction
04/21/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
Drawing code
3
Owner type
03
Owner location
Kyoto, JP
Examiner
GEARHART, DAVID JAMES
Current location
Historical data usage
Holders and representatives
Holders
NIPPON SHINYAKU CO., LTD.
Representatives
N. Alexander Nolte Nolte Lackenbach Siegel
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical preparations for the treatment of myelofibrosis; pharmaceutical preparations for the treatment of eosinophilic granulomatosis with polyangiitis; pharmaceutical preparations for the treatment of endometriosis; pharmaceutical preparations for the treatment of retinal dystrophies; pharmaceutical preparations for the treatment of Leber congenital amaurosis; pharmaceutical preparations for the treatment of cardiomyopathy; pharmaceutical preparations for the treatment of muscular dystrophy; pharmaceutical preparations for the treatment of Mucopolysaccharidosis; pharmaceutical preparations for the treatment of Lysosomal disease
Publications
History of USPTO decisions and trademark events.
25 publications found
COC.
CORRECTION UNDER SECTION 7 - PROCESSED
04/02/2026
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
04/02/2026
ES7R
TEAS SECTION 7 REQUEST RECEIVED
12/29/2025
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
12/02/2025
R.PR
REGISTERED-PRINCIPAL REGISTER
12/02/2025
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
10/14/2025
PUBO
PUBLISHED FOR OPPOSITION
10/14/2025
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
10/08/2025
ERRR
ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED
09/12/2025
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
08/29/2025
XAEC
EXAMINER'S AMENDMENT ENTERED
08/29/2025
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
08/29/2025
GNEA
EXAMINERS AMENDMENT E-MAILED
08/29/2025
CNEA
EXAMINERS AMENDMENT -WRITTEN
08/29/2025
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
08/28/2025
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
08/28/2025
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
08/28/2025
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
06/26/2025
GNRT
NON-FINAL ACTION E-MAILED
06/26/2025
CNRT
NON-FINAL ACTION WRITTEN
06/26/2025
DOCK
ASSIGNED TO EXAMINER
06/25/2025
MDSC
NOTICE OF DESIGN SEARCH CODE E-MAILED
06/16/2025
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
06/16/2025
NWAP
NEW APPLICATION ENTERED
01/16/2025
Continuous trademark protection
Get notified about every new filing that threatens N NS PHARMA or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.